Participants who are scheduled to have open ventral hernia repair (OVHR) will be asked to take part in this study. The purpose of this study is to find out if placing Microlyte (which is a dissolvable sheet coated in silver) on the surgical incision is better than placing nothing on the surgical incision when it comes to decreasing the chance of surgical site infections. The study device has been cleared by the Food and Drug Administration (FDA) for use on surgical incisions. A total of 280 participants will be included in the study. Participation will last for about 90 days.
The aim of our study is to assess the impact of Microlyte-AG® (Imbed Biosciences, Fitchburg, WI), a silver-coated bioabsorbable matrix, on surgical site infection (SSI) on patients undergoing clean open ventral hernia repair (OVHR) at Carolinas Medical Center/Atrium Health (Charlotte, NC), Prisma Health-Upstate (Greenville, SC), and Mission Health/HCA Healthcare (Asheville, NC). Those who agree to participate in the study will undergo the following: Information will be collected, including demographics, past medical and surgical history, and hospital outcomes. On the day of surgery, participants will be "randomized" into one of the study groups listed below. * Group 1: The study device will be cut into strips and placed in the surgical incision * Group 2: Nothing will be placed in the surgical incision For both groups, the surgical incision will then be closed with absorbable sutures, which is the usual treatment. Participants will be seen by the study doctor 30 and 90 days after surgery for a checkup. At the 30-day visit, participants will have a physical examination, and the study doctor will check to see if any complications have happened since the last visit. The 90-day follow-up visit can be done in person or over the telephone and will be done to check and see if there have been any problems with the healing of the surgical incision.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Microlyte will be cut into strips and placed on the subcutaneous space
Mission Hospital/HCA Healthcare
Asheville, North Carolina, United States
Carolinas Medical Center/Atrium Health
Charlotte, North Carolina, United States
Prisma Health
Greenville, South Carolina, United States
Rate of SSI following clean OVHR with and without Microlyte.
SSI, which is the primary outcome that will be measured for the study will be as an infection of the skin or subcutaneous tissues as clinically determined by the physician caring for the patient
Time frame: 90 days
Rate of other wound complications, including superficial wound breakdown, seroma formation, and mesh infection, with/without Microlyte.
Other wound complications will be defined based on a combination of clinical assessment and review of postoperative notes and imaging
Time frame: 90 days
Rate of short-term readmissions with and without Microlyte
Short-term readmissions
Time frame: 30-days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.